Insmed Q4 2025 Preview: Arikayce Growth and Brensocatib Regulatory Path
Insmed (INSM) enters its Q4 2025 earnings cycle at a critical inflection point as it transitions from a single-product company to a multi-asset commercial powerhouse. Investors are focused on Arikayce's revenue trajectory and the upcoming regulatory submission for brensocatib following its successful Phase 3 ASPEN trial.